ZetaMet™ Receives Health Canada Authorization for Phase 2a Study in Treating Metastatic Bone Lesions
Technology is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone Study will examine the safety and efficacy of ZetaMet™ in the treatment of metastatic bone lesions as part of advanced stage cancer therapy Study is targeting Stage 4 breast cancer patients who have metastatic…